GB201709076D0 - Parp inhibitors for use in methods of treating cancer - Google Patents
Parp inhibitors for use in methods of treating cancerInfo
- Publication number
- GB201709076D0 GB201709076D0 GBGB1709076.2A GB201709076A GB201709076D0 GB 201709076 D0 GB201709076 D0 GB 201709076D0 GB 201709076 A GB201709076 A GB 201709076A GB 201709076 D0 GB201709076 D0 GB 201709076D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- methods
- treating cancer
- parp inhibitors
- parp
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709076.2A GB201709076D0 (en) | 2017-06-07 | 2017-06-07 | Parp inhibitors for use in methods of treating cancer |
| PCT/EP2018/064873 WO2018224536A1 (en) | 2017-06-07 | 2018-06-06 | Parp inhibitors for use in treating cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709076.2A GB201709076D0 (en) | 2017-06-07 | 2017-06-07 | Parp inhibitors for use in methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201709076D0 true GB201709076D0 (en) | 2017-07-19 |
Family
ID=59349931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1709076.2A Ceased GB201709076D0 (en) | 2017-06-07 | 2017-06-07 | Parp inhibitors for use in methods of treating cancer |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201709076D0 (en) |
| WO (1) | WO2018224536A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113035272B (en) * | 2021-03-08 | 2023-09-05 | 深圳市新合生物医疗科技有限公司 | Method and device for obtaining immunotherapeutic new antigen based on intein cell variation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101370497B (en) * | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | Combination products and uses comprising PARP inhibitors and cytotoxic agents |
| WO2012015937A2 (en) * | 2010-07-29 | 2012-02-02 | The Regents Of The University Of Michigan | Parp1 targeted therapy |
| US20160184356A1 (en) * | 2013-03-15 | 2016-06-30 | Ke Jian Jim Liu | Arsenic-based treatment of cancers and inflammatory disorders |
| EP3626832B1 (en) * | 2014-11-25 | 2024-06-12 | The Brigham and Women's Hospital, Inc. | Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease |
| WO2017013237A1 (en) * | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| MX381475B (en) * | 2015-08-20 | 2025-03-12 | Ipsen Biopharm Ltd | COMBINATION THERAPY USING LIPOSOMAL IRINOTECAN AND A POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR FOR THE TREATMENT OF CANCER. |
-
2017
- 2017-06-07 GB GBGB1709076.2A patent/GB201709076D0/en not_active Ceased
-
2018
- 2018-06-06 WO PCT/EP2018/064873 patent/WO2018224536A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018224536A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284324A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| IL272948B1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| IL256874B (en) | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers | |
| IL256799A (en) | Use of a combination of dbait molecule and parp inhibitors to treat cancer | |
| IL266182A (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| IL254842A0 (en) | Therapeutic compositions and methods of use for treating cancer | |
| IL274198A (en) | Use of nox inhibitors for treatment of cancer | |
| IL268722A (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| IL272473A (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| HK40006114A (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| HRP20191391T1 (en) | Use of a combination of dbait molecule and parp inhibitors to treat cancer | |
| PL2999789T3 (en) | Method for selection of hdis3 pin domain inhibitors and use of hdis3 pin domain inhibitors for cancer treatment | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |